Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


loader
  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators

    $4,750.00

    This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the US, 5EU, Japan, and RoW markets for tissue-engineered skin replacements (epidermal, dermal, and multilayer equivalents, and amniotic tissue grafts) and active wound repair modulators (growth factors, gene therapy agents, and stem cells).

    September 23, 2020
    Find out more
  • Xadago

    Read More

    Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels.

    June 21, 2018
    Find out more
  • Xalkori

    Read More

    Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor

    August 30, 2018
    Find out more
  • Xarelto

    Read More

    Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan.

    March 15, 2018
    Find out more
  • xeljanz report

    Xeljanz

    Read More

    While Xeljanz (tofacitinib; Pfizer/Takeda) demonstrated positive efficacy in its Phase III clinical trial

    program, its future in psoriasis is uncertain.

    October 17, 2017
    Find out more
  • Ximency

    Read More

    Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.

    November 6, 2017
    Find out more
  • Xofigo

    Read More

    Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases.

    January 18, 2018
    Find out more
  • Xolair

    Read More

    Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma.

    February 16, 2018
    Find out more
  • Xtandi

    Read More

    Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA.

    January 18, 2018
    Find out more
  • Xultophy

    Read More

    Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes.

    November 7, 2017
    Find out more
  • Xyntha

    Read More

    Xyntha is a recombinant factor VIII (rfVIII) therapy approved for the treatment of hemophilia A.

    Although Pfizer has taken steps to enhance the product by improving the manufacturing processes

    and developing an application device for the therapy, Xyntha’s target patient population will be

    reduced by competitor therapies approved for prophylactic use.

    May 4, 2018
    Find out more
  • Yervoy

    Read More

    Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) is an intravenous fully humanized immunoglobulin-G1 monoclonal antibody that targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).

    May 23, 2018
    Find out more
  • Yescarta

    Read More

    Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.

    January 30, 2019
    Find out more
  • Ygalo

    Read More

    Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine

    August 9, 2018
    Find out more
  • Yonsa

    Read More

    Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.

    January 18, 2018
    Find out more
Page 83 of 85
Page 83 of 85«‹8182838485›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top